![]() The most common diagnoses among respondents were chronic lymphocytic leukemia, non-Hodgkin lymphoma, Waldenström macroglobulinemia and myeloma. Of those, 3,574 had a least one dose of the vaccine and reported their experience with adverse events. (Update: press release now available here).īetween February 22 and April 8, 2021, 4,505 blood cancer patients and survivors (average age 64 years) completed a survey about their experiences with COVID-19 and vaccination. Data about the subset of patients who agreed to participate will be available by summer 2021. Every patient who was planning to be vaccinated was also offered the opportunity to provide blood samples to test for the COVID-19 spike and neutralizing antibody. This preliminary report includes vaccine adverse events data from 3,574 Registry participants who had at least one dose of any currently authorized COVID-19 vaccine (BNT162b2 from Pfizer and BioNTech, mRNA-1273 from Moderna, JNJ-78436735 from Janssen Pharmaceuticals Companies of Johnson & Johnson). The Registry includes patients and survivors with every type of blood cancer participants include those on active treatment, post-treatment or in a “watch and wait” period (“treatment naïve”). The Leukemia & Lymphoma Society National Patient Registry, created in honor of Michael Garil, is collecting data to provide more specific information about how people with blood cancer respond to COVID-19 virus and/or COVID-19 vaccination. Therefore, how people with blood cancer respond to the COVID-19 vaccinations is unknown. The vaccine clinical trials were streamlined and essentially excluded people with a current or past diagnosis of cancer. Blood cancer patients and survivors should get the third dose as soon after 28 days as possible.īecause of the health emergency created by the COVID-19 virus, three COVID-19 vaccinations have been authorized by the U.S. FDA for Emergency Use Administration (EUA). The minimum wait time between the second and third dose is 28 days. The CDC advises using the same vaccine for all three doses, but if the original vaccine is not available or unknown, either vaccine can be given. ![]() LLS recently reported that most blood cancer patients benefit from an additional COVID-19 vaccine dose. “I urge all blood cancer patients and survivors to get vaccinated-including with the third dose, unless told otherwise by their doctor.” “Most reactions to these vaccines-including a third dose-are mild and temporary,” said LLS Chief Medical Officer Dr. These results are based on patient reports from more than 2,400 participants in the LLS National Patient Registry who received a third dose of either Moderna or Pfizer COVID-19 vaccines between Augand September 20, 2021. Allergic reactions including rash and shortness of breath were rare, occurring in less than 1% of those vaccinated. ![]() The most common systemic reactions were fatigue (31%), muscles aches/pain (18%) and headache (17%). The Trish Greene Back to School ProgramĬonsistent with earlier two-dose findings, the most commonly reported local reactions after a third COVID-19 mRNA vaccine (Moderna or Pfizer) among blood cancer patients were sore arm (57%) and injection site pain (18%).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |